FCCC LOGO Faculty Publications
Li H , Bitler BG , Vathipadiekal V , Maradeo ME , Slifker M , Creasy CL , Tummino PJ , Cairns P , Birrer MJ , Zhang RG
ALDH1A1 Is a Novel EZH2 Target Gene in Epithelial Ovarian Cancer Identified by Genome-Wide Approaches
Cancer Prevention Research. 2012 Mar;5(3) :484-491
PMID: WOS:000300987800015    PMCID: PMC3294119   
Back to previous list
Abstract
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy in the United States. EZH2 silences gene expression through trimethylating lysine 27 on histone H3 (H3K27Me3). EZH2 is often overexpressed in EOC and has been suggested as a target for EOC intervention. However, EZH2 target genes in EOC remain poorly understood. Here, we mapped the genomic loci occupied by EZH2/H3K27Me3 using chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) and globally profiled gene expression in EZH2-knockdown EOC cells. Cross-examination of gene expression and ChIP-seq revealed a list of 60 EZH2 direct target genes whose expression was upregulated more than 1.5-fold upon EZH2 knockdown. For three selected genes (ALDH1A1, SSTR1, and DACT3), we validated their upregulation upon EZH2 knockdown and confirmed the binding of EZH2/H3K27Me3 to their genomic loci. Furthermore, the presence of H3K27Me3 at the genomic loci of these EZH2 target genes was dependent upon EZH2. Interestingly, expression of ALDH1A1, a putative marker for EOC stem cells, was significantly downregulated in high-grade serous EOC (n = 53) compared with ovarian surface epithelial cells (n 10, P < 0.001). Notably, expression of ALDH1A1 negatively correlated with expression of EZH2 (n 63, Spearman r = -0.41, P < 0.001). Thus, we identified a list of 60 EZH2 target genes and established that ALDH1A1 is a novel EZH2 target gene in EOC cells. Our results suggest a role for EZH2 in regulating EOC stem cell equilibrium via regulation of ALDH1A1 expression. Cancer Prev Res; 5(3); 484-91. (C) 2011 AACR.
Notes
Li, Hua Bitler, Benjamin G. Vathipadiekal, Vinod Maradeo, Marie E. Slifker, Michael Creasy, Caretha L. Tummino, Peter J. Cairns, Paul Birrer, Michael J. Zhang, Rugang NCI FCCC-UPenn ovarian cancer SPORE[P50 CA083638]; SPORE career development award; DOD[OC093420]; NCI[CA-009035-35] This work was supported in part by a NCI FCCC-UPenn ovarian cancer SPORE (P50 CA083638) pilot project and SPORE career development award ( to R. Zhang) and a DOD ovarian cancer academy award (OC093420 to R. Zhang). B. G.Bitler is supported by an NCI postdoctoral training grant (CA-009035-35). R. Zhang is an Ovarian Cancer Research Fund (OCRF) Liz Tilberis Scholar. 37 Amer assoc cancer research Philadelphia 901st